Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial

BACKGROUND: Direct oral anticoagulants (DOACs) pose a great challenge for physicians in life-threatening bleeding events. The aim of this study was to test the efficacy of reversing the DOAC rivaroxaban using four-factor PCC (prothrombin complex concentrate), a non-specific reversing agent. METHODS:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thromb J
Main Authors: Schenk, Bettina, Goerke, Stephanie, Beer, Ronny, Helbok, Raimund, Fries, Dietmar, Bachler, Mirjam
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5763793/
https://ncbi.nlm.nih.gov/pubmed/29344007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12959-017-0158-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados